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Abstract
Background: Biochemical markers including interleukins (ILs) has been proposed for
early diagnosis of asphyxia.
Objective: This study has aimed to systematically review the significance of IL
measurements in the diagnosis of perinatal asphyxia.
Materials and Methods: PubMed, Cochrane Library, Web of Science, Embase, and
Scopus databases before 2017 were searched for the following keywords: asphyxia,
neonatal, interleukin, and diagnosis. A total of 13 out of 300 searched papers were
finally selected for evaluation. Interleukins under study were IL6 and interleukin 1𝛽
(IL-1𝛽). Interleukins had been measured in 10 studies by serum samples, 2 studies by
samples of Cerebro Spinal Fluid (CSF), and 1 study by sample of umbilical cord blood.
The inclusion criteria were: studies on neonates, with adequate information from the
test results and studies using markers other than ILs to detect asphyxia; however,
studies with only abstracts available were excluded.
Results: Research on the issue suggests that IL6 > 41 Pg/dl has the sensitivity of 84.88%
and the specificity of 85.43%, whereas IL-1𝛽 > 4.7 Pg/dl has the sensitivity of 78%
and specificity of 83% in the diagnosis of neonatal asphyxia. Among diagnostic ILs
for neonatal asphyxia, combination of IL6 and IL-1𝛽 had the highest sensitivity, that is,
92.9%.
Conclusion: IL6 and IL-1𝛽 of serum samples were used in the early diagnosis of
perinatal asphyxia and are useful predictors for the outcomes of perinatal asphyxia
and its intensity. In addition, simultaneous evaluation of IL-1𝛽 and IL6 can improve the
sensitivity of the early diagnosis of perinatal asphyxia.
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1. Introduction
Perinatal asphyxia has been defined as the lack
of oxygen that occurs either before, during, or after
birth (1). It is a significant cause of perinatal morbid-
ity and mortality as well as neurological disabilities
in the surviving babies (2, 3). Annually, four million
babies are born with perinatal asphyxia of whom,
800,000 die, and the same number experience
adverse clinical outcomes (4). The mortality and
morbidity rates among patients with moderate or
severe Hypoxic Ischemic Encephalopathy (HIE) is
very high. Half of patients with severe HIE will
die, while almost all survivors suffer from neuro-
developmental deficits, cerebral palsy, epilepsy,
and learning disorders (5, 6). A previous two-
yr follow-up study has reported 26% mortality
in asphyxic neonates, with 28% experiencing
developmental delay (3). Several pathophysiologic
mechanisms of brain damage in neonates are
linked to HIE. Early assessment of the severity
of a HIE-induced acute brain injury can be very
useful for the prevention or treatment decisions
in such neonates (7). The prediction of perina-
tal asphyxia is done using multiple assessments
including the electronic monitoring of fetal heart
rate during labor, cord or fetus pH measurements,
meconium-stained amniotic fluid, Apgar score, the
severity of HIE, prooxidant Antioxidant Balance
(PAB), blood markers (Nucleated red blood cells
(NRBC) in umbilical cord blood), and multiple
organs impairments. None of these factors alone
are sufficient and combinations of parameters
are clinically used for early diagnosis of perinatal
asphyxia (8, 9). Recent studies have focused on the
inflammatory cytokines such as IL-1𝛽, IL6, and IL8
for early diagnosis of brain damage. As interleukins
(ILs) are known as one of the early inflamma-
tory responses to infections, they are potentially
important in early diagnosis and hence proper
management of both infectious and non-infectious
conditions before the establishment of fulminant
stage. The inflammatory cytokines are involved
in the biochemical pathways leading to ischemic-
hypoxic injury (10, 11). The role of inflammation in
neonatal Central Nervous System (CNS) injuries
as well as the role of cytokines as mediators of
injuries have been identified (12). It is likely that
the pathophysiology of perinatal asphyxia has a
close relationship with the inflammatory mediators
such as cytokines (13). Many of these cytokines
such as IL-1𝛽, IL6, IL8, IL10, and IL12 increase
during the inflammatory responses (14). A study has
shown that cytokines cause brain damage through
direct injury to the white matter, weakening the
germinal matrix endothelium, brain hemorrhage,
and inflammatory reactions caused by microglia
and astrocytes (15). Although cytokines play a
role in the regulation of cell apoptosis in CNS as
well as leukocyte differentiation, proliferation, and
infiltration, the precise role of pro-inflammatory
cytokines such as IL6 as the main mediator in the
development of brain damage is still unknown (16).
Although several studies have been conducted on
the relationship between the ILs and infectious
conditions, however, comparison of their value in
confirmation or rule out of the diagnosis of infection
has not been fully discussed yet. Identification of
biochemical markers such as IL may be useful for
early diagnosis of asphyxia. Early diagnosis of peri-
natal asphyxia helps to provide better health care
and improved outcomes. Brain injury is also a com-
mon cause of sever morbidity with poor outcomes
and high mortality during the perinatal period.
The current systematic review was conducted
aiming at the identification of neonatal perinatal
asphyxia by IL levels.
2. Materials and Methods
2.1. Selection of ILs for the diagnosis of
neonatal asphyxia
After an initial review of the literature, a list of
ILs was prepared to conduct a systematic review.
Page 304 https://doi.org/10.18502/ijrm.v17i5.4598
International Journal of Reproductive BioMedicine Interleukins in diagnosis of perinatal asphyxia
The articles examining the role of ILs in the
diagnosis of neonatal asphyxia were studied. In
this regard, articles containing ILs such as IL-1, IL-
6, or combinations of both were analyzed for the
diagnosis of neonatal asphyxia.
2.2. Search strategy
PubMed, Cochrane Library, Web of Science,
Embase, and Scopus databases were used for
this systematic review. “Asphyxia,” “neonatal
asphyxia,” “perinatal asphyxia,” “interleukin,” and
“diagnosis” were the search keywords. All articles
in English and Persian between and consisting
1997 and 2016 were searched.
2.3. Inclusion criteria
Articles with the following criteria were selected
for this review: (1) Neonates as the study population;
(2) Neonatal asphyxia as the specified study; (3) ILs
must be examined for the diagnosis or prediction of
neonatal asphyxia in umbilical cord blood, serum,
or Cerebro Spinal Fluid (CSF); and (4) Adequate
information from the test results.
2.4. Exclusion criteria
Animal studies; articles that used other markers
for the diagnosis of asphyxia rather than ILs; and
articles with only abstract available were excluded
from the study.
2.5. Data extraction and quality
assessment of the articles
The full-text articles were downloaded and the
extracted data were collected in Microsoft Excel
with the following titles: the authors’ names and
surnames, years of publication, methods, study
areas, case groups, control groups, type of IL, loca-
tions of sampling, time for measuring IL, sensitivity,
specificity; positive predictive value, negative pre-
dictive value, and the results of the investigation.
Initially, 300 studies were collected using EndNote
software and the duplicate articles (𝑛 = 115) were
excluded from the review. According to the title
and abstract, 65 more articles were excluded. A
total of 107 other articles were also removed due
to incomplete data, unavailability of full text, animal
studies, uncertainty of the study type and the target
group. Finally, 13 related articles underwent further
analysis (Figure 1).
Records identified through 












Additional records identified 
through other sources (n = 100) 
Records after duplicates removed (n = 300) 
Records screened (n = 120) Records excluded (n = 180) 
Full-text articles assessed for eligibility (n = 120) 
Full-text articles excluded, 
with reasons (n = 107) 
Studies included in qualitative synthesis (n = 13) 
Figure 1. Search strategy and selected articles.
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3. Results
A total of 13 out of 300 articles with a total
sample size of 1120 neonates were examined. Eight
articles discussed IL6 (61.54%), two studies (15.38%)
described about IL-1𝛽, and three articles (23.08%)
were related to the combination of both ILs.
3.1. The number of the studies on ILs
The review of studies conducted from 1997 to
2016 showed that IL6 is themost frequently studied
biomarker among IL family. Interleukins had been
measured in 10 studies on serum samples (76.92%),
2 on CSF samples (15.39%), and 1 on umbilical cord
blood samples (7.69%). All studies were prospec-
tive ones.
3.2. Heterogeneity of the articles
Studies on the relationship between IL and
diagnosis of perinatal asphyxia were different in
terms of inclusion criteria, sample size, sampling
location, time of assessment, and the diagnostic
value of ILs. Only five studies have discussed the
diagnostic value of IL (38.46%). The cutoff values
for both IL6 and IL-1𝛽 were 11.91-100, and negative
predictive values of ILs were different in the articles
under study (Figure 2, Table I).
Figure 2. The sensitivity, specificity, positive, and negative
predictive values (%) of IL6 in prediction of asphyxia∗. and its
adverse outcomes†.
3.3. IL6 (eight studies)
In a study on serum levels of IL6 at birth, 24
and 48 hr after delivery for 37 neonates with
perinatal asphyxia and 45 healthy neonates serum
concentrations of IL6 was reported as 43 times
higher in asphyxiated neonates with HIE and 1.9
times higher in asphyxiated neonates without
HIE compared to the healthy neonates. Serum
concentrations of IL6 were increased in neonates
with asphyxia after birth and this was associated
with the severity of encephalopathy and poor
outcomes. The sensitivity, specificity, positive, and
negative predictive value of IL6 in prediction of
asphyxia and its adverse outcomes are shown
in Figure 1. So following cerebrospinal system
injury, IL6 plays an important role and its serum
concentrations can be a useful predictor of HIE
outcomes (1). Another study comparing the IL6 in
50 neonates with non-infectious perinatal asphyxia
with 113 healthy neonates at similar time points
showed that the average concentrations of IL6 in
neonates with HIE were 376 times higher than the
healthy babies and 5.5 times higher in neonates
with asphyxia without HIE. A critical relationship
was also found between IL6 and the degree of
HIE as well as neuro-developmental outcomes at
two yr. Regardless of the outcomes, serum IL6
concentration was significantly lower in the first 24
and 48 hr after birth. Umbilical cord concentration
of IL6 > 100 pg/ml had the sensitivity and specificity
of 70.8% and 80.9%, respectively, in predicting
moderate to severe HIE. It was concluded that
IL6 measurement in the umbilical cord blood of
newborns with perinatal asphyxia may be useful in
early detection of neonates with high risk of brain
damage and adverse outcomes (17). A study on the
neurological markers (IL6) in perinatal asphyxia
and its relationship with different stages of HIE
was performed on 100 asphyxic and 100 healthy
neonates with blood samplings in the first and
third days of birth. The results showed that the
average concentration of serum IL6 on the third
day of birth of asphyxic neonates declined. There
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was also a negative relationship between IL6
concentrations in the first and third days of birth.
The IL6 concentration had a reverse correlation
with the HIE stages (Stages 1-3) within the 1st
to the 3rd day of birth. In addition, there was
a negative relationship between the first and
third day of life in terms of IL6 concentrations in
various stages of HIE. It was concluded that IL6
concentration increases after birth asphyxia, and
this increase is associated with the severity of
HIE and poor outcomes (18). In a study on the
predictors of early HIE in Egypt, serum IL6 was
measured in the first 12 hr of life in 27 perinatal
asphyxic as well as 25 healthy neonates. The
HIE group showed significantly higher IL6 levels
compared to the controls. IL6 measurements
have also been performed in the CSF of full-term
neonates with HIE. This prospective study was
performed on 20 healthy newborns (no sepsis or
meningitis; 1 and 2 min Apgar scores ≥ 9) and 15
neonates in the case group (with asphyxia and
Apgar score of ≤ 4 in the first minute and ≤ 6 in
the fifth minute, umbilical cord blood pH < 7.20
or lactate > 3 mmol/liter in the umbilical artery
blood and need for artificial ventilation for at least
two minutes after birth). The CSF samples were
collected within the first 48 hr after birth to identify
IL6. The results showed that the average IL6 in the
case group (157.5 pg/ml) was significantly higher
than the control group (4.1 pg/ml). The researchers
concluded that IL6 levels in term neonates with
HIE is higher than the control group (19). A different
study aiming at the evaluation of IL6 in CSF after
perinatal asphyxia and its relationship with early
and late nervous observations was conducted
on 20 infants, among whom, 3 cases had no HIE
(stage 0), 5 infants were at stage 1, 6 infants at
stage 2, and 6 infants at stage 3 of HIE. The IL6
concentration in CSF (from 8 to 90 hr of birth) in
infants at stage 3 of HIE was higher than those
at stage 0 to 2. Infants with brain damage and
adverse outcomes showed higher CSF levels
of IL6. The increase in CSF IL6 after perinatal
asphyxia was related to the intensity of HIE, brain
damage, and neurological outcomes. The
researchers concluded that IL6 may be involved in
hypoxic-ischemic brain damage (20). A study on
the clinical significance of serum IL6 in neonates
with HIE was performed on 74 neonates with HIE
along with 74 healthy neonates. An increase in the
inflammatory mediators was associated with the
severity of the disease and positively correlated
with prognosis. They reported high levels of
IL6 in neonates with HIE. High concentrations
of IL6 in infants with HIE suggests that these
inflammatory mediators play an important role in
the development and prognosis of the disease
(21). Serum concentrations of 50 asphyxic and 20
healthy neonates were measured on days 1, 3, and
7 after birth in a study on the relationship between
IL6 and brain damage in perinatal asphyxia. The
results showed that IL6 levels in asphyxic neonates
reduced within a week after birth and reverted to
the normal level on day 7 after birth; however, the
IL6 levels were significantly lower in neonates with
brain damage compared with neonates with no
brain injury. As a conclusion, IL6 levels increase in
neonatal asphyxia; hence, it can be involved in the
pathophysiology of neonatal asphyxia (22).
3.4. IL-1𝛽 (two articles)
Serum levels of IL-1𝛽 were studied in 38
neonates with non-infectious perinatal asphyxia
(blood pH < 7.2, low Apgar score, and fetal distress
symptoms) and 41 healthy neonates (natural babies
with no clinical signs of asphyxia during the first
week after delivery) at birth as well as 24 and
48 hr after the delivery. The serum levels of IL-
1𝛽 in neonates with HIE were five times more
than asphyxiated newborns without HIE and six
times higher than healthy babies. Also, a significant
relationship was found between IL-1𝛽 and neonatal
outcomes at discharge. The sensitivity, specificity,
positive, and negative predictive value of IL-1𝛽 in
prediction of the occurrence of asphyxia and its
adverse outcomes are shown in Figure 3.
https://doi.org/10.18502/ijrm.v17i5.4598 Page 307





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































International Journal of Reproductive BioMedicine Boskabadi et al.
Figure 3. The sensitivity, specificity, positive, and negative
predictive values (%) of IL-1𝛽 in the prediction of the occurrence
of asphyxia∗. and its adverse outcomes†.
The researchers concluded that the increase in
serum levels of IL-1𝛽 in asphyxic neonates is a pre-
dictor of poor outcomes. In other words, serum IL-1𝛽
is a predictor for the severity of perinatal asphyxia
and its short-term neural outcomes (23). A different
prospective study was conducted on the predictive
value of plasma and CSF concentrations of IL-1𝛽 in
the outcomes of 30 term neonates with HIE. Blood
and CSF samples were collected within the first 24
hr after birth. Five babies died immediately after
hypoxia. The neurological examination and Denver
Developmental Screening Test were performed at
one yr of age. Eleven neonates had normal and
fourteen had abnormal neurological findings or
abnormal Denver Developmental Screening Test.
The results indicated that the CSF concentration
of IL-1𝛽 in unhealthy infants was significantly higher
than healthy ones. However, no significant differ-
ence was found in the plasma concentrations of IL-
1𝛽 in two groups. Patients with CSF samples taken
within six hr of hypoxia had higher levels of IL-1𝛽
compared to those with sampling after six hr of
hypoxia. The researchers concluded that IL-1𝛽 level
is correlated with CNS damage after hypoxia and
can be a useful predictor for HIE (24).
3.5. Combination of IL6 and IL-1𝛽
(three articles)
Combination of IL6 and IL-1𝛽 at birth was studied
in 38 infectious infants with perinatal asphyxia (pH
< 7.2, low Apgar score, and fetal distress symptoms)
and 47 healthy infants. Serum concentrations of
IL6 and IL-1𝛽 were significantly higher in infants
with perinatal asphyxia compared to the healthy
ones (88.15 vs. 6.74pb/ml for IL6 and 16.88 vs.
3.34pb/ml for IL-1𝛽). The sensitivity and specificity
of IL6 and IL-1𝛽 are shown in Figure 4. The turning
points for IL6 and IL-1𝛽 were 11.91 pb/ml and 3.35
pb/ml, respectively. The researchers concluded
that simultaneous assessment of IL6 and IL-1𝛽 can
improve the sensitivity and specificity for early
diagnosis of perinatal asphyxia. In addition, the
assessment of the combination of IL-1𝛽 and IL6 was
the best indicator for perinatal asphyxia (25).
Figure 4. The sensitivity and specificity (%) of IL6 and IL-1𝛽 in
prediction of diagnosis of perinatal asphyxia.
In a different study on evaluation of the markers
for early diagnosis of brain damage in the preterm
low-birth-weight infants with perinatal asphyxia, 29
infants with perinatal asphyxia and 28 healthy
infants were involved. Serum IL6 and IL-1𝛽
were measured in the first 24 hr and the 3rd
and 7th days of birth. The study results showed
Page 310 https://doi.org/10.18502/ijrm.v17i5.4598
International Journal of Reproductive BioMedicine Interleukins in diagnosis of perinatal asphyxia
that serum IL6 and IL-1𝛽 were significantly higher
in infants with perinatal asphyxia in the first 24
hr after birth compared to the healthy infants.
Neurologic evaluation of 14 infants with perinatal
asphyxia and 12 healthy ones at 18 months of age
revealed that 8 infants with perinatal asphyxia had
abnormal findings that were associated with serum
levels of IL6 and IL-1𝛽 in 24 hr after birth. The
researchers concluded that increased levels of pro-
inflammatory cytokines are the primary findings
for the future neurological disorders in infants with
asphyxia (26). In an evaluation of the inflammatory
cytokines in 55 healthy and 45 infants with HIE,
serum levels of IL6 and IL-1𝛽 were measured at
birth, 24, and 72 hr after birth. A significant increase
was found in IL6 and IL-1𝛽 in infants with HIE at
three time points (27). The combination of IL6 and
IL-1𝛽 had the highest average sensitivity (92.9%)
and specificity (85.43%) among diagnostic ILs in
asphyxiated infants (Table II).
Table II. Average diagnostic value of interleukins (IL) in relation to infant asphyxia
Biomarker Mean Cutoff (pg/ml) Mean Sensitivity Limit (%) Mean Specificity (%)
IL6 >41.35 84.88 85.43
IL1-𝛽 >4.68 77.9 83.37
IL6 ± IL1-𝛽 >17.25 92.9 43.5
4. Discussion
Perinatal asphyxia is a common and serious
problem that results in annually almost a million
infant deaths in the world. Perinatal asphyxia may
also have negative impacts on all main body organs
(3). HIE increases the quick expression of inflam-
matory cytokines of brain (IL1 and IL6) (28). IL6 level
is one of the powerful predictors of HIE outcomes
such as death and long-term neuro-developmental
problems (17). It appears as a considerable product
among inflammatory cytokines in the pathogenesis
of perinatal asphyxia (29). IL6 is as an inflammatory
mediator in brain injury and plays a central role
in the inflammatory responses (30). It is not clear
whether IL6 has a devastating effect on neurons
or healing effect after brain ischemic damage (31).
IL6 may be released as a protective response
after hypoxic-ischemic brain damages. It acts as
a cytokine with two pro-inflammatory and anti-
inflammatory properties (32). IL6 has been shown
to play two roles in cerebral ischemia: as an
inflammatory mediator during the acute phase and
as a neurotrophic mediator within the acute and
long-term stages (33). Higher levels of IL6 have
been reported in infants with perinatal asphyxia
and hypothermia (34). IL6 is involved in the induc-
tion of acute reactions and control the inflam-
matory responses causing a reduction in pro-
inflammatory cytokines and an increase in anti-
inflammatory molecules during acute cerebral
ischemia stage (35). IL6 increases in CSF fluid
in asphyxic infants and is related with the sever-
ity of HIE (20). A direct relationship has been
reported between the CSF levels of IL6 and TNF-
𝛼 and neurological prognosis after acute cere-
bral ischemia in adults (36). It has been shown
that CSF levels of IL6 are significantly higher
in infants with severe neurological observations
compared to mild or moderate encephalopathy
(20). Increased IL6 in the CSF has been shown to
be related with the severity of HIE, brain injury,
and neurological outcomes at 12 or 72 hr after
perinatal asphyxia (20). Serum concentrations of
IL6 increased approximately 12 hr after birth (1). A
recent study reported an increase in serum levels
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of IL6 in infants with HIE (32). Animal studies have
shown an increase in the peak serum levels of IL6
in rats with HIE in 6 hr after creating HIE so that the
concentration of IL returns to the base level after 20
hr (28); however, researchers have not specified a
certain turning point for IL6 that predicts long-term
adverse outcomes. A significant relationship has
been reported between the serum concentrations
of IL6 and Sarnat encephalopathy grading (31).
Also, increased levels of IL6, IL11, and IL13 have
been reported in dried blood samples of infants
with cerebral palsy (37). The results of an animal
study showed that the serial injection of synthetic
IL6 prevents learning disabilities and delays the
loss of neurons (38). In another study, the increase
in serum IL6 was associated with poor outcomes
or death in infants with perinatal asphyxia (39). An
increased IL6 in amniotic fluid and cord blood were
associated with outcomes such as cerebral palsy
and periventricular leukomalacia, respectively (40).
Cohort Study of Ahearne and co-worker is the
first report that measured the association of IL-16
in neonates with perinatal asphyxia at birth and
long-term outcome. IL-16 is an early biomarker of
severe injury that determine the long-term progno-
sis of infants with HIE.
Serum IL6 had 86% positive predictive value
and 100% specificity in predicting moderate to
severe HIE (41). Available studies have indicated
that IL6> 41 pg/dL had sensitivity and specificity
of 88.84% and 85.43%, respectively, in the diag-
nosis of neonatal asphyxia. Therefore, the highest
sensitivity and specificity are for the diagnosis of
asphyxia related to IL6. IL-1𝛽 in umbilical cord is
a major bio-outcome for brain injury whose levels
are significantly high in infants with HIE and predict
severeHIE and adverse outcomes in 6 to 12months
of age (42).
Increased CSF concentrations of IL-1𝛽 are asso-
ciated with neurologic outcomes after perinatal
asphyxia. It could be concluded that IL-1𝛽 has neu-
rotrophic and neuroprotective results. However,
it is not clear whether IL-1𝛽 is involved in the
destruction or repair of neurons after ischemic
brain injuries (31). CSF levels of TNF-𝛼 and IL-1𝛽
were higher in term infants with HIEwho developed
nervous disorders in one age (43). Neuroprotective
antagonist effects of IL-1𝛽 receptor against brain
damages before or after exposure to hypoxia have
already been reported (44). The available studies
showed that IL-1𝛽> 4.7 pg/dl had sensitivity and
specificity of 78% and 83%, respectively, in the
diagnosis of neonatal asphyxia. IL-1𝛽 and IL6 are
significantly increased in birth asphyxia and the
rate of increase is associated with the severity of
encephalopathy. Simultaneous assessment of IL-1𝛽
and IL6 is the best indicator of perinatal asphyxia
(25). IL-1𝛽 and IL6 levels have been reported to
be significantly higher in infants with perinatal
asphyxia compared to the control group in 24 hr
after birth (26). In another study, serum levels of
IL6, IL8, and IL10 were higher in infants with severe
asphyxia (death or poor outcome) than those with
asphyxia but no poor outcome (39). Serum concen-
trations of IL-1𝛽 and IL6 were significantly higher in
infants with perinatal asphyxia than that in healthy
infants. Simultaneous assessment of IL-1𝛽 and IL6
improved the sensitivity and specificity of early
diagnosis of perinatal asphyxia. Assessment of
combined IL-1𝛽 and IL6 was suggested as the best
indicator of perinatal asphyxia (25). Available stud-
ies indicated that simultaneous assessment of IL-1𝛽
and IL6 had the sensitivity of 93% and specificity of
43.5% in the diagnosis of neonatal asphyxia. The
current review is the only study that has examined
the role of IL in the diagnosis of perinatal asphyxia.
Limitations of this study include the lack of access
to unpublished articles and reports, inappropriate
and low-quality reports, limited number of articles
and infeasibility of accurate judgments about their
effectiveness, lack of similar definitions for case
groups, lack of cutoff point calculations, and lack
of diagnostic value of IL in all the studies under
review.
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5. Conclusion
Serum and CSF concentrations of interleukins
IL6 and IL-1𝛽 increased after asphyxia and the
rate of increase was associated with the severity
of asphyxia and adverse outcomes. Therefore,
combination of IL6 and IL-1𝛽 can be used as a
potential substantially powerful marker for early
diagnosis of perinatal asphyxia. Further studies are
required in order to identify more involved ILs and
standardize their cutoff values in early diagnosis of
neonatal asphyxia.
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